Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

Sponsor
Peking Union Medical College
Study ID
NCT06926192
Status
Recruiting
Apply to this trial

Conditions

  • Hidradenitis Suppurativa (Acne Inversa)
  • Hidradenitis Suppurativa (HS)
  • Secukinumab

Eligibility Criteria

Sex
ALL
Age
N/A - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.

Key Dates

Start date
Jan 1, 2020
Status verified
Apr 2025
Primary completion
Dec 31, 2024
Completion
Jun 21, 2025

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Moderate to severe hidradenitis suppurativa

Primary Outcome Measure

HiSCR [ Time Frame: week 52 ]

Central Contacts

Related Studies